Merck & Co., Inc. (MRK)
Should You Buy, Sell or Hold MRK Stock After Q1 Earnings Beat?
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.
Merck Q1 Earnings & Sales Beat Estimates, '25 EPS Outlook Cut
MRK posts better-than-expected first-quarter results but trims its 2025 EPS outlook due to anticipated one-time charges.
Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks
The two companies have been talking for months about a deal
Merck & Co., Inc. (MRK) Q1 2025 Earnings Call Transcript
Merck & Co., Inc. (NYSE:MRK ) Q1 2025 Earnings Conference Call April 24, 2025 9:00 AM ET Corporate Participants Peter Dannenbaum - Senior Vice President, Investor Relations Rob Davis - Chairman and Chief Executive Officer Caroline Litchfield - Chief Financial Officer Dean Li - President of Merck Research Labs Conference Call Participants Geoff Meacham - Citi Tim Anderson - Bank of America Luisa Hector - Berenberg Vamil Divan - Guggenheim Securities Chris Schott - JPMorgan James Shin - Deutsche Bank Steve Scala - TD Cowen Alex Hammond - Wolfe Research Umer Raffat - Evercore Akash Tewari - Jefferies Mohit Bansal - Wells Fargo Operator Thank you for standing by. Welcome to the Merck & Company Incorporated Rahway, New Jersey, USA Quarter One Sales and Earnings Conference Call.
Merck (MRK) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Merck lowers profit outlook due to expected $200M tariff hit
Merck & Co Inc (NYSE:MRK, ETR:6MK) has lowered its full-year earnings forecast due to an expected $200 million hit from global tariffs, notably levies between the US and China. The company now expects 2025 earnings per share (EPS) in the range of $8.82 to $8.97, down from its prior forecast of $8.88 to $9.03.
2 Blue-Chip Stocks Brushing Off Earnings Beats
Pharmaceutical giant Merck & Co Inc (NYSE:MRK) has reversed its premarket lead, down 2% at $77.20 at last glance.
Merck (MRK) Q1 Earnings and Revenues Top Estimates
Merck (MRK) came out with quarterly earnings of $2.22 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.07 per share a year ago.
Merck Cuts 2025 View on Tariffs, Charges
Merck's first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 adjusted earnings projection, partly to account for recently imposed tariffs.
Merck Q1 Earnings Coming Up: Should You Buy the Stock Now?
When Merck reports first-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, Keytruda.
Merck: Now A Single-Digit P/E With Double-Digit EPS Growth, Technical Support
The Health Care sector outperformed the S&P 500 in 2025, with XLV returning -1.5% YTD compared to SPY's -10% decline. Despite mixed performance, Merck's stock has dropped 37% since mid-2024, but I maintain a buy rating due to long-term support and potential growth drivers. Merck's Q4 results beat expectations, but concerns over Gardasil and Keytruda's patent expirations have weighed on the stock.
Merck & Co.: Pipeline Resilience To Unlock Value
I initiate coverage on Merck & Co., Inc. with a Strong Buy rating and a $139 price target, driven by resilient execution and robust product depth. Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. New product launches like WINREVAIR are exceeding expectations and offsetting pipeline risk.
